Product Image

No-Flush Niacin (Inositol Hexanicotinate) 500 mg

Solgar
4.8
★ ★ ★ ★ ★
(581 ratings)
Niacin 400 mg
Product Image
Score80
A reasonable no-flush niacin option with a plausible niacin-and-inositol split. The bound form should be stated more directly, and heart-specific expectations should remain modest.
How scoring works
Quantity:100 Capsule(s) • (100 servings)
Goals:
Cardiovascular Support
Heart Health

Score 80

A reasonable no-flush niacin option with a plausible niacin-and-inositol split. The bound form should be stated more directly, and heart-specific expectations should remain modest.
How scoring works
$18.92($0.18 per serving)
Pure Formulas
$ 20.24
iHerb
$ 18.92
Vitacost
$ 20.57
Daily Vita
$ 20.24
Report prices

Analysis

The combination appears designed to deliver inositol hexanicotinate, a slow-releasing no-flush niacin form. That may appeal to people who cannot tolerate nicotinic acid flushing.

The ingredient lines separate niacin and inositol rather than naming the complete bound compound. This leaves avoidable uncertainty about identity even though the amounts fit the intended complex.

No-flush niacin can support vitamin B3 intake, but it should not be expected to mirror nicotinic acid for lipid-focused use. The product fits tolerance-first supplementation better than a targeted heart plan.

Who is it for
  • Adults who dislike nicotinic-acid flushing
  • People seeking vitamin B3 with inositol
  • Users prioritizing tolerance
Best for
  • No-flush niacin supplementation
  • General vitamin B3 intake
  • Longer-term tolerance-focused routines

Pros

  • Niacin and inositol amounts are disclosed
  • Lower-flush positioning
  • Reasonable serving value

Cons

  • Bound compound is not directly named
  • Less dependable for lipid-focused use
  • Large amount exceeds basic nutrient needs

Warnings

  • Do not treat no-flush niacin as interchangeable with nicotinic acid for lipid management.
  • The large vitamin B3 amount may still cause stomach upset or liver-related effects during prolonged use.
  • Avoid stacking it with other niacin products without checking total intake.

Nutrient quality

82 Highest impact

Inositol hexanicotinate is a clearly named no-flush niacin derivative. The amount is meaningful for this less direct niacin form.

.

Ingredient transparency

81 Highest impact

All meaningful active amounts are clearly disclosed. The supplied data does not include a complete inactive ingredient list.

.

Customer satisfaction

70 High impact

The aggregate satisfaction measure is strong and supported by adequate volume. Missing feedback themes leave recurring complaints and purpose fit uncertain.

.

Value for money

85 Highest impact

The price is reasonable for the formula quality and dose. Each serving provides good cost efficiency.

.
Report analysis

Goals

Cardiovascular Support
Impact
Moderate effect
D+ Goal FitC+ Strength of SupportF CoverageA Formula Quality
Niacin · 400 mg

Inositol hexanicotinate is marketed as a no-flush niacin source, but it does not have the same dependable lipid effects as prescription-dose nicotinic acid. The formula therefore has a plausible cardiovascular intent with limited clinical certainty.

The chemical form and amounts are clearly disclosed in a streamlined capsule. A substantial no-flush amount should not be treated as a substitute for clinician-managed lipid therapy.

Study evidence
Niacin Supportive 136 studies
Heart Health
Impact
Moderate effect
D- Goal FitC- Strength of SupportF CoverageA- Formula Quality

Inositol hexanicotinate is a no-flush niacin source, but it does not have the reliable lipid effects associated with therapeutic nicotinic acid. The stated 400 mg niacin amount therefore overstates how confidently the formula can support heart-related lipid goals.

The focused two-ingredient design is transparent and avoids unnecessary additions. It is better viewed as a specialized niacin product than as broad cardiovascular support.

Study evidence
Niacin Supportive 105 studies

Ingredients

IngredientAmount per serving
Niacin
400 mg
Inositol
100 mg
Gluten Free Adults 18–50 Vegan Kosher Dairy Free Sugar Free Vegetarian
Report overview
Niacin · 400 mg OverallScore85
B- Active Ingredient Quality & BioavailabilityA Dose, Safety & Label TransparencyA+ Value

Inositol hexanicotinate is a no-flush niacin form that may suit people prioritizing comfort, though it can require more material than nicotinic acid for cardiovascular use. The capsule provides a substantial amount with clear no-flush positioning. Its serving cost is favorable for this niacin form.

Loading alternative details
Report alternatives

Sources

Published studies used for the product analysis and the top-ranked studies for each ingredient and goal.

  1. Effect of niacin therapy on cardiovascular outcomes in patients with coronary artery disease.
    Duggal JK; Singh M; Attri N; Singh PP; Ahmed N; Pahwa S; Molnar J; Singh S; Khosla S; Arora R · Journal of cardiovascular pharmacology and therapeutics · 2010
    Meta-analysis5,137 participants7 studies pooledHeart Health forNiacin
  2. Role of Niacin in Current Clinical Practice: A Systematic Review.
    Garg A; Sharma A; Krishnamoorthy P; Garg J; Virmani D; Sharma T; Stefanini G; Kostis JB; Mukherjee D; Sikorskaya E · The American journal of medicine · 2017
    Meta-analysis35,206 participants13 studies pooledHeart Health forNiacin
  3. Relationship of lipoproteins to cardiovascular events: the AIM-HIGH Trial (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides and Impact on Global Health Outcomes).
    Guyton JR; Slee AE; Anderson T; Fleg JL; Goldberg RB; Kashyap ML; Marcovina SM; Nash SD; O'Brien KD; Weintraub WS; Xu P; Zhao XQ; Boden WE · Journal of the American College of Cardiology · 2013
    Randomized trial3,414 participantsHeart Health Cardiovascular Support forNiacin
  4. Assessment of the Role of Niacin in Managing Cardiovascular Disease Outcomes: A Systematic Review and Meta-analysis.
    D'Andrea E; Hey SP; Ramirez CL; Kesselheim AS · JAMA network open · 2020
    Meta-analysis35,760 participants17 studies pooledHeart Health forNiacin
  5. Exploring the Cardiovascular Impacts of Oral Nicotinamide: A Comprehensive Narrative Review.
    Shoukfeh R; Tisack AM; Lim HW; Mohammad TF · Journal of drugs in dermatology : JDD · 2025
    Narrative reviewHeart Health forNiacin
  6. The ARBITER 6-HALTS Trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6-HDL and LDL Treatment Strategies in Atherosclerosis): final results and the impact of medication adherence, dose, and treatment duration.
    Villines TC; Stanek EJ; Devine PJ; Turco M; Miller M; Weissman NJ; Griffen L; Taylor AJ · Journal of the American College of Cardiology · 2010
    Randomized trial315 participantsHeart Health forNiacin
  7. The current state of niacin in cardiovascular disease prevention: a systematic review and meta-regression.
    Lavigne PM; Karas RH · Journal of the American College of Cardiology · 2013
    Meta-analysis9,959 participants11 studies pooledCardiovascular Support forNiacin
  8. Effects of niacin on apo A1 and B levels: a systematic review and meta-analysis of randomised controlled trials.
    Saboori S; Yousefi Rad E; Tammam J; Thondre PS; Coe S · The British journal of nutrition · 2024
    Meta-analysis12 studies pooledCardiovascular Support forNiacin
  9. Niacin improves lipid profile but not endothelial function in patients with coronary artery disease on high dose statin therapy.
    Philpott AC; Hubacek J; Sun YC; Hillard D; Anderson TJ · Atherosclerosis · 2013
    Randomized trial66 participantsCardiovascular Support forNiacin
  10. Supplemental Vitamins and Minerals for Cardiovascular Disease Prevention and Treatment: JACC Focus Seminar.
    Jenkins DJA; Spence JD; Giovannucci EL; Kim YI; Josse RG; Vieth R; Sahye-Pudaruth S; Paquette M; Patel D; Blanco Mejia S; Viguiliouk E; Nishi SK; Kavanagh M; Tsirakis T; Kendall CWC; Pichika SC; Sievenpiper JL · Journal of the American College of Cardiology · 2021
    Meta-analysisCardiovascular Support forNiacin
  11. Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: the ADMIT study: A randomized trial. Arterial Disease Multiple Intervention Trial.
    Elam MB; Hunninghake DB; Davis KB; Garg R; Johnson C; Egan D; Kostis JB; Sheps DS; Brinton EA · JAMA · 2000
    Randomized trial468 participantsCardiovascular Support forNiacin
  12. Effect of lipid-lowering therapies on lipoprotein(a) levels: a comprehensive meta-analysis of randomized controlled trials.
    Xie S; Galimberti F; Olmastroni E; Carugo S; Catapano AL; Casula M; META-LIPID Group · Atherosclerosis · 2025
    Meta-analysis145,314 participants147 studies pooledCardiovascular Support forNiacin
  13. Extended-release niacin vs gemfibrozil for the treatment of low levels of high-density lipoprotein cholesterol. Niaspan-Gemfibrozil Study Group.
    Guyton JR; Blazing MA; Hagar J; Kashyap ML; Knopp RH; McKenney JM; Nash DT; Nash SD · Archives of internal medicine · 2000
    Randomized trial173 participantsCardiovascular Support forNiacin
  14. Equivalent efficacy of a time-release form of niacin (Niaspan) given once-a-night versus plain niacin in the management of hyperlipidemia.
    Knopp RH; Alagona P; Davidson M; Goldberg AC; Kafonek SD; Kashyap M; Sprecher D; Superko HR; Jenkins S; Marcovina S · Metabolism: clinical and experimental · 1998
    Randomized trial223 participantsCardiovascular Support forNiacin
  15. Differential effect of two nicotinic acid preparations on low-density lipoprotein subclass distribution in patients classified as low-density lipoprotein pattern A, B, or I.
    Superko HR; McGovern ME; Raul E; Garrett B · The American journal of cardiology · 2004
    Randomized trial180 participantsHeart Health forNiacin
  16. The effects of extended-release niacin on carotid intimal media thickness, endothelial function and inflammatory markers in patients with the metabolic syndrome.
    Thoenes M; Oguchi A; Nagamia S; Vaccari CS; Hammoud R; Umpierrez GE; Khan BV · International journal of clinical practice · 2008
    Randomized trial50 participantsHeart Health forNiacin
  17. Effect of niacin on endothelial function: a systematic review and meta-analysis of randomized controlled trials.
    Sahebkar A · Vascular medicine (London, England) · 2014
    Meta-analysis441 participants7 studies pooledHeart Health forNiacin